AU2003298770A1 - Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines - Google Patents

Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines Download PDF

Info

Publication number
AU2003298770A1
AU2003298770A1 AU2003298770A AU2003298770A AU2003298770A1 AU 2003298770 A1 AU2003298770 A1 AU 2003298770A1 AU 2003298770 A AU2003298770 A AU 2003298770A AU 2003298770 A AU2003298770 A AU 2003298770A AU 2003298770 A1 AU2003298770 A1 AU 2003298770A1
Authority
AU
Australia
Prior art keywords
wta
infection
staphylococcal
aureus
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003298770A
Other languages
English (en)
Other versions
AU2003298770A2 (en
Inventor
John Fitzgerald Kokai-Kun
Sascha A Kristian
Christopher Weidenmaier
Andreas Peschel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosynexus Inc
Original Assignee
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosynexus Inc filed Critical Biosynexus Inc
Publication of AU2003298770A2 publication Critical patent/AU2003298770A2/en
Publication of AU2003298770A1 publication Critical patent/AU2003298770A1/en
Priority to AU2010200341A priority Critical patent/AU2010200341A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2003298770A 2002-12-02 2003-12-01 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines Abandoned AU2003298770A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010200341A AU2010200341A1 (en) 2002-12-02 2010-01-29 Wall Teichoic Acid as a Target for Anti-Staphylococcal Therapies and Vaccines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43022502P 2002-12-02 2002-12-02
US60/430,225 2002-12-02
PCT/US2003/038132 WO2004050846A2 (en) 2002-12-02 2003-12-01 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010200341A Division AU2010200341A1 (en) 2002-12-02 2010-01-29 Wall Teichoic Acid as a Target for Anti-Staphylococcal Therapies and Vaccines

Publications (2)

Publication Number Publication Date
AU2003298770A2 AU2003298770A2 (en) 2004-06-23
AU2003298770A1 true AU2003298770A1 (en) 2004-06-23

Family

ID=32469426

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003298770A Abandoned AU2003298770A1 (en) 2002-12-02 2003-12-01 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
AU2010200341A Abandoned AU2010200341A1 (en) 2002-12-02 2010-01-29 Wall Teichoic Acid as a Target for Anti-Staphylococcal Therapies and Vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010200341A Abandoned AU2010200341A1 (en) 2002-12-02 2010-01-29 Wall Teichoic Acid as a Target for Anti-Staphylococcal Therapies and Vaccines

Country Status (6)

Country Link
US (1) US20040247605A1 (cg-RX-API-DMAC10.html)
EP (1) EP1567868A4 (cg-RX-API-DMAC10.html)
JP (1) JP2006514636A (cg-RX-API-DMAC10.html)
AU (2) AU2003298770A1 (cg-RX-API-DMAC10.html)
CA (1) CA2507711A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004050846A2 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US20070071682A1 (en) * 2005-08-22 2007-03-29 Kokai-Kun John F Methods for testing vaccine candidates against bacterial infection in rodents
CA2625580A1 (en) * 2005-10-11 2007-04-26 Iogenetics, Llc Targeted biocides
KR20100072228A (ko) * 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009151561A2 (en) * 2008-06-12 2009-12-17 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
KR20110124060A (ko) * 2010-05-10 2011-11-16 부산대학교 산학협력단 Ｗｔａ를 유효성분으로 함유하는 백신 조성물
WO2013071409A1 (en) 2011-11-18 2013-05-23 National Research Council Of Canada (Nrc) Clostridium difficile lipoteichoic acid and uses thereof
CN103383354B (zh) * 2012-05-03 2016-11-09 北京博迈世纪生物技术有限公司 一种检测肠毒素sea的磁微粒化学发光试剂盒的检测方法
KR20150024315A (ko) * 2012-05-07 2015-03-06 재단법인 목암생명공학연구소 포도상구균 감염 예방용 백신 조성물
PE20160715A1 (es) * 2013-05-31 2016-08-01 Genentech Inc Anticuerpos frente a acidos teicoicos de pared y conjugados
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
MX369758B (es) * 2013-05-31 2019-11-20 Genentech Inc Anticuerpos anti-acido teicoico de pared y conjugados.
TWI632157B (zh) * 2013-05-31 2018-08-11 建南德克公司 抗壁磷壁酸抗體（ａｎｔｉ－ｗａｌｌ ｔｅｉｃｈｏｉｃ ａｃｉｄ ａｎｔｉｂｏｄｉｅｓ）及結合物
WO2015183041A1 (ko) * 2014-05-29 2015-12-03 주식회사 녹십자 포도상구균 감염 질환의 예방 또는 치료용 조성물
KR20170086536A (ko) * 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
WO2017010845A1 (ko) * 2015-07-15 2017-01-19 재단법인 목암생명과학연구소 포도상구균 감염 질환의 예방 또는 치료용 조성물
JP2019519509A (ja) * 2016-05-18 2019-07-11 ゲンマブ ビー．ブイ． 感染性疾患の治療における抗体およびその使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250262A (en) * 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
US5139933A (en) * 1989-09-26 1992-08-18 Vicam, L.P. Assay method for detecting listeria
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5290707A (en) * 1991-11-25 1994-03-01 The United States Of America As Represented By The Secretary Of The Army Method for detection of microorganisms
US5367058A (en) * 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
JP3814290B2 (ja) * 1993-12-09 2006-08-23 エスクナー，ハインリッヒ 抗原用のアジュバントおよびその製法ならびに用途
US6350597B1 (en) * 1994-01-13 2002-02-26 E. I. Du Pont De Nemours & Company Riboflavin synthase genes and enzymes and methods of use
US6203997B1 (en) * 1994-06-08 2001-03-20 Sepsis, Inc. Quantitation of analytes in whole blood
EP0807185B9 (en) * 1995-01-30 2002-12-11 Lunamed AG Antitumor preparations containing a lipoteichoic acid from steptococcus
ATE328069T1 (de) * 1995-10-13 2006-06-15 Harvard College Phosphopantethenyltransferasen und deren verwendungen
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5889171A (en) * 1997-07-18 1999-03-30 Smithkline Beecham Corporation TarF
SK732000A3 (en) * 1997-07-23 2001-03-12 Ambi Inc Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6585973B1 (en) * 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
ES2281977T3 (es) * 1998-12-22 2007-10-01 Microscience Limited Proteinas de estreptococo del grupo b y su utilizacion.
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
US6365156B1 (en) * 1999-04-16 2002-04-02 Osel, Inc. Method for improving the half-life of soluble viral-specific ligands on mucosal membranes
US6974700B2 (en) * 1999-06-14 2005-12-13 Martin Levine Kit for use in predicting refractory periodontal disease
US20020051793A1 (en) * 2000-09-12 2002-05-02 Drabick Joseph J. Lipoteichoic acid immunogenic compositions and methods of making and using thereof
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
AU2003203079B9 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
FR2842210B1 (fr) * 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
EP2228379A1 (en) * 2003-04-25 2010-09-15 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
US7422755B2 (en) * 2004-01-15 2008-09-09 The United States Of America As Represented By The Department Of Health And Human Services Antimultiorganism glycoconjugate vaccine
KR100596443B1 (ko) * 2004-04-27 2006-07-05 주식회사 하이닉스반도체 다수 뱅크 구조 디램을 위한 리프레시 제어회로 및 그 방법
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
JP2008537885A (ja) * 2005-04-15 2008-10-02 ノース・キャロライナ・ステイト・ユニヴァーシティ 細菌の付着およびストレス耐性を修飾する方法および組成物
US7521535B2 (en) * 2006-09-20 2009-04-21 The Board Of Regents For Oklahoma State University Anti-microbial defensin-related peptides and methods of use

Also Published As

Publication number Publication date
WO2004050846A3 (en) 2005-03-17
AU2003298770A2 (en) 2004-06-23
AU2010200341A1 (en) 2010-02-18
CA2507711A1 (en) 2004-06-17
JP2006514636A (ja) 2006-05-11
EP1567868A4 (en) 2008-02-06
US20040247605A1 (en) 2004-12-09
WO2004050846A8 (en) 2004-09-16
WO2004050846A2 (en) 2004-06-17
EP1567868A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
AU2010200341A1 (en) Wall Teichoic Acid as a Target for Anti-Staphylococcal Therapies and Vaccines
US7777017B2 (en) Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
AU2009202762B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US20030224000A1 (en) Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
AU2009210372B2 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
EP2464665B1 (en) Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation
WO2020098701A1 (zh) 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
JP6371758B2 (ja) 抗ブドウ球菌抗体、その製造方法並びにその使用
US7169903B2 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
JP2005514053A6 (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
AU2012254925B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
AU2002365440A1 (en) Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 JUN 2005

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted